MedPath

The Decline in Walking Performance in Adults With Cerebral Palsy - Influence of Performance Fatigability

Not Applicable
Terminated
Conditions
Muscle Spasticity
Paralysis; Cerebral
Interventions
Other: Fatigability assessment
Registration Number
NCT06163950
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Due to an early brain injury occurring in antenatal or postnatal, cerebral palsy (CP) causes alteration in motor function with posture and gait disorders. It is commonly observed motor performance degradation during adulthood, and the underlying pathophysiology remains poorly known.

Detailed Description

One of the hypotheses to explain the decline in walking capacities in adults with CP is their greater fatigability, that could be related to energy overconsumption (due to the specific biomechanical constraints of their walking pattern) and/or the occurrence of early sarcopenia affecting the compensatory muscle mechanisms commonly seen in children to compensate for architectural disorders and posture alterations. To optimize prevention and/or therapy in these patients, it is crucial to better understand the aetiology of fatigability and its role in the decline in walking performance.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
30
Inclusion Criteria

Common for CP and healthy volunteers:

  • Capable of walking for six minutes without stopping
  • Capable of consenting to the tests

Specific for the CP group

  • GMFCS I or II at age 18
  • Spastic diplegic cerebral palsy
Exclusion Criteria
  • Counter-indications to the test procedures
  • Mental retardation or intelligence quotient (IQ) below 80
  • Accompanying diseases not allowing for the test setup
  • Major surgeries altering performance in the last six months
  • Injection of botulin altering maximal force production in the last three months
  • Refusing to sign the consent form

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Patients with cerebral palsyFatigability assessmentA specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
Healthy peopleFatigability assessmentA specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
Primary Outcome Measures
NameTimeMethod
Neuromuscular fatigueWeek : 6

Neuromuscular fatigue, defined as the decrease in maximal voluntary force (in % of the resting value) developed in isometric knee extension following a standardized fatigue protocol.

Secondary Outcome Measures
NameTimeMethod
Maximum voluntary force torque measurement of the knee flexor musclesWeek : 2

Measurement of the (in Nm) of the knee flexor muscles in isometric and dynamic contraction.

Maximum voluntary force torque measurement of knee extensor musclesWeek : 4

Measurement of the (in Nm) of the knee extensor muscles in isometric and dynamic contraction.

Measurement of joint amplitude (in °)Week : 6

Evaluation of the passive muscular properties of the dominant leg, on the knee flexor muscles, and on the plantar flexor and knee extensor muscles

Evaluation of neuromuscular fatigueWeek : 6

The decrease in muscle twitch evoked by electrical nerve stimulation (in %) (peripheral fatigue)

VO2max (in mL/min/kg)Week : 6

Cardiorespiratory capacity will be assessed by measuring maximal oxygen consumption (VO2max (in mL/min/kg)) in an incremental cyclo-ergometer test.

Level of voluntary activation measurementWeek : 6

Measurement of the level of voluntary activation (in %) determined by the force increment obtained following electrical stimulation of the motor nerve during a muscle condition of maximum contraction.

Time (in seconds) taken during the 10-meter walk testWeek : 6

Quantitative walking performance will be assessed by measuring the time (in seconds) taken during the 10-meter walk test

Walking Quality evaluationWeek : 6

The quality of walking will be evaluated (only in CP subjects) by a Quantified Gait Analysis (QGA) allowing the measurement of spatio-temporal parameters, joint kinematics and kinetics as well as muscle activity during walking. will be evaluated (only in CP subjects) by a Quantified Gait Analysis (QGA) allowing the measurement of spatio-temporal parameters, joint kinematics and kinetics as well as muscle activity during walking.

Maximum voluntary force torque measurement of the plantar flexorWeek : 2

Measurement of the (in Nm) of the plantar flexor in isometric and dynamic contraction.

Measurement of passive torque (in Nm)Week : 6

Evaluation of the passive muscular properties of the dominant leg, on the knee flexor muscles, and on the plantar flexor and knee extensor muscles

Time (in s) taken in the "Get Up and Go" testWeek : 6

Quantitative walking performance will be assessed by measuring the time (in s) taken in the "Get Up and Go" test

The distance covered (in m) in the 6-minute walking testWeek : 6

Quantitative walking performance will be assessed by measuring the distance covered (in m) in the 6-minute walking test

Berg Balance ScaleWeek : 6

Postural control (or balance) will be assessed (only in CP subjects) by the Berg Balance Scale (BBS) score. This score, ranging from 0 to 56, is an index to measure functional balance.

0 means high risk of falling; person needs a wheelchair 56 means no risk of falling; the person has functional balance

Trial Locations

Locations (1)

Centre Hospitalier de Saint-Etienne

🇫🇷

Saint-Étienne, France

© Copyright 2025. All Rights Reserved by MedPath